Published in Cancer Weekly, October 26th, 2004
Juvaris' novel and potent immunostimulation technology will be tested in rodent tumor models established by Claxton at Penn State University to evaluate the impact on leukemia using either an antigen-specific immunotherapeutic AML vaccine (JuvaVax) or a non-antigen immunostimulant (JuvImmune) to augment immune responsiveness.
These approaches are supported by preclinical data generated by Juvaris and preliminary studies...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.